Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2-(4-benzylphenoxy)ethyl)diethylamine
2. Bzphoet-diethylammonium Chloride
3. Depmpe
4. Dppe
5. Dppe Hydrochloride
6. Ethanamine, N,n-diethyl-2-(4-(phenylmethyl)phenoxy)-, (2ar-(2aalpha,4beta,4abeta,6beta,9alpha(alphar*,betas*),11alpha,12alpha,12aalpha,12balpha))-
7. N,n-diethyl-2-((4-phenylmethyl)phenoxy)-ethanamine Hydrochloride
8. N,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine
9. N,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine Hydrochloride
10. N,n-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine
11. N,n-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine Hydrochloride
12. Tesmilifene Hydrochloride
1. 98774-23-3
2. 2-(4-benzylphenoxy)-n,n-diethylethanamine
3. Tesmilifene [inn]
4. N,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine
5. Depmpe
6. Chembl26424
7. I43t3id6g2
8. N,n-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine
9. N,n-diethyl-2-[4-benzylphenoxy]ethanamine
10. Ethanamine, N,n-diethyl-2-(4-(phenylmethyl)phenoxy)-
11. Ncgc00024762-02
12. N,n-diethyl-2-(4-benzylphenoxy)ethanamine
13. Dsstox_cid_25661
14. Dsstox_rid_81038
15. Dsstox_gsid_45661
16. Unii-i43t3id6g2
17. Cas-98774-23-3
18. Ethanamine, N,n-diethyl-2-[4-(phenylmethyl)phenoxy]-
19. Ymb1002
20. Tocris-0743
21. Tesmilifene [mi]
22. 2-((alpha-phenyl-p-tolyl)oxy)triethylamine
23. Tesmilifene [who-dd]
24. Schembl112525
25. Zinc2139
26. Dtxsid1045661
27. Chebi:93414
28. Bcp09123
29. Tox21 110924
30. Tox21_110924
31. Bdbm50085260
32. Tox21_110924_1
33. Db04905
34. [2-(4-benzylphenoxy)ethyl]diethylamine
35. Ncgc00024762-01
36. Ncgc00024762-03
37. Ncgc00024762-04
38. Ncgc00024762-05
39. N,n-diethyl-2-(p-benzylphenoxy)ethylamine
40. Db-103604
41. [2-(4-benzyl-phenoxy)-ethyl]-diethyl-amine
42. Triethylamine, 2-(.alpha.-phenyl-p-tolyloxy)-
43. Brd-k80315159-051-01-2
44. Q27095558
| Molecular Weight | 283.4 g/mol |
|---|---|
| Molecular Formula | C19H25NO |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 8 |
| Exact Mass | 283.193614421 g/mol |
| Monoisotopic Mass | 283.193614421 g/mol |
| Topological Polar Surface Area | 12.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 250 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Intended for the treatment of various forms of cancer.
Histamine Antagonists
Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
Hepatic
Although the exact mechanism of action is not known, one study (PMID: 16413681) proposes that tesmilifene may be an activating p-gp substrate, which enables the p-gp pump to extrude typical p-gp substrates (such as anthracyclines or taxanes) more efficiently. This process consumes ATP, since the p-gp is absolutely, and highly dependent on ATP hydrolysis. The mechanism of cell death is likely to result not from the presence of chemotherapy inside the cell (in fact the chemotherapy is extruded) but, directly or indirectly, from the enhanced consumption of ATP. The ATP may be consumed below a threshold necessary for survival, or, (more likely) the enhanced ATP production required to maintain ATP levels may result in the generation of reactive oxygen species (ROS) to an extent that overwhelms the cells ability to inactivate them. The result would be additional cell death, but only in the mdr+ population. The doxorubicin would continue to act on the drug sensitive remainder of the cell population, but without the help of tesmilifene.
ABOUT THIS PAGE
A Tesmilifene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tesmilifene, including repackagers and relabelers. The FDA regulates Tesmilifene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tesmilifene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tesmilifene manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tesmilifene supplier is an individual or a company that provides Tesmilifene active pharmaceutical ingredient (API) or Tesmilifene finished formulations upon request. The Tesmilifene suppliers may include Tesmilifene API manufacturers, exporters, distributors and traders.
click here to find a list of Tesmilifene suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Tesmilifene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tesmilifene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tesmilifene GMP manufacturer or Tesmilifene GMP API supplier for your needs.
A Tesmilifene CoA (Certificate of Analysis) is a formal document that attests to Tesmilifene's compliance with Tesmilifene specifications and serves as a tool for batch-level quality control.
Tesmilifene CoA mostly includes findings from lab analyses of a specific batch. For each Tesmilifene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tesmilifene may be tested according to a variety of international standards, such as European Pharmacopoeia (Tesmilifene EP), Tesmilifene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tesmilifene USP).
LOOKING FOR A SUPPLIER?
